СПИСОК ЛИТЕРАТУРЫ

  1. Montenez J.P., Van Bambeke F., Mingeot-Leclercq M.P., et al. Azithromycin causes an accumulation of lipids in lysosomes of cultured cells: biochemical mechanism and potential relationship with its long time retention in cell. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. A85.
  2. Lalak N.J., Morris D.L. Azithromycin clinical pharmacokinetics. Clin. Pharmacokinet., 1993, 25: 370-374.
  3. Mazzei Т., Surrenti С., Novelli A., et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J. Antimicrob. Chemother., 1993, 31 (suppl. С): 57-63.
  4. Shiba K., Shindo N., Sakai 0. Pharmacokinetics of azithromycin in patients with renal failure. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 363-366.
  5. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 95-101.
  6. Muller 0. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 137-146.
  7. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 153-162.
  8. Tseng A., Dolovich L., Salit I. Azithromycin ototoxicity in HIV patients. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995: abstr. LM19.
  9. Dunn C.J., Barradell L.B. Azithromycin: a review of its pharmacologocal properties and use as 3-day therapy in respiratory tract infections. Drugs, 1996, 51: 483-505.
  10. Harris S., Hilligoss D.M., Colangelo P.M., et al. Azithromycin and terfenadine: lack of drug interaction. Clin. Pharmacol. Ther., 1995, 58: 310-315.
  11. Ljutic D., Rumboldt Z. Possible interaction between azithromycin and cyclisporin: a case report. Nephrone, 1995, 70: 130.
  12. Thalhammer F., Hollenstein U., Janata K., et al. Interactions between azithromycin and digitoxin. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 5234.
  13. Vincent J., Foulds G., Apseloff G., et al. Interaction of rifabutin with the macrolides azithromycin and clarithromycin. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. A29.
  14. von Rosenstiel N.-A., Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf., 1995, 13: 105-122.
  15. Association of the British Pharmaceutical Industry. Zithromax. In: Walker G. (Ed.). APBI Data Sheet Compendium 1994-95. London, 1994: 1285-1286.
  16. Dubois J., Saint-Pierre C., Sampalis J., et al. Azithromycin vs penicillin-V in the management of acute tonsillitis/pharyngitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.33.
  17. Portier H., Garre M., Lucht F., et al. Azithromycin 3 days, or 5 days versus penicillin V 10 days in the treatment of streptococcal pharyngitis in adults. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. LM-25.
  18. Carbon C., Hotton J.M., Pepin L.F., et al. Economic analysis of antibiotic regimens in pharyngitis: a prospective naturalistic comparison of azithromycin versus roxithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 14.03.
  19. Tihonov V., Stratchunsky L., Asmolovsky V. Comparison of azithromycin and erythromycin in the treatment of sinusitis. In: The 5th European Congress of Clinical Microbiology and Infectious Diseases. Oslo, 1991: abstr. 229.
  20. Bosatra A., Tattoni P., Podda M., et al. Study on effectiveness and tolerance to azithromycin vs. roxithromycin in the treatment of patients with upper respiratory tract infections. Clin. Ter., 1994, 144: 27-30.
  21. Muller 0. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J. Antimicrob. Chemother., 1996, 37 (suppl. C): 83-92.
  22. O'Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J. Antimicrob. Chemother., 1996, 37 (suppl. C): 71-81
  23. Bisetti A., Grassi L., Morelli G., et al. Confronto tra azitromicina ed eritromicina nel trattamento delle infezioni acute delle vie respiratorie superiori ed inferiori in pazienti adulti. Farm. Ter., 1992, 9: 135-142.
  24. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J. Antimicrob. Chemother., 1996, 37 (suppl. C): 115-124.
  25. Mertens J.C.C., van Barneveld P.W.C., Asin H.R.G., et al. Doublehlind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis, Antimicrob, Agents Chemother., 1992, 36: 1456-1459.
  26. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J. Antimicrob. Chemother., 1996, 37 (suppl. C); 93-101.
  27. Zachariah J. A randomized, comparative study to evaluate the efficacy and tiolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J. Antimicrob. Chemother., 1996, 37 (suppl. C): 103-113.
  28. Treadway G., Castillo Z., Smith A., et al. Treatment of community-acquired pneumonia: an open, multicenter, comparative study of azithromycin and amoxicillin/clavulanic acid. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996: abstr. 12.13.
  29. Kinasewitz G., Wood R.G. Azithromycin versus cefaclor treatment for acute bacterial pneumonia. Eur. J. Clin. Microbiol. Infect. Dis., 1991, 10: 872-877.
  30. Medina Asensio J., Jerez Basurgo B., Brusint Olivares B., et al. Azithromycin compared with erythromycin as initial therapy for community acquired pneumonia: a prospective randomized study. In: The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1993: abstr. K6.
  31. Pontani D., The Azithromycin Pneumonia Study Group. A randomized, multicenter study to compare the efficacy and toleration of azithromycin and clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 5239.
  32. Kuzman I., Schonwald S., Culig J. Azithromycin in the treatment of community acquired legionnairs' disease. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, abstr. 1.05.
  33. Donowitz G.R., Mandell G.L. Acute pneumonia; In: Principles and Practice of Infectious Diseases. Mandell G.L., Bennett J.E., Dolin R. (Eds.). 4th ed. New York, etc., 1995: 619-637.
  34. Zithromax, data on file. Pfizer, 1997.
  35. Hammerschlag M.R., Gregory W.W., Schwartz D.B., et al. Azithromycin in the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. K-138.
  36. Cassell G.H., Gregory W.W., Greenberg R.N., et al. Efficacy of azithromycin in the treatment of community-acquired pneuminia due to Mycoplasma pneumoniae. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. K-139.
  37. Kobayashi H., Shimada K., Nakata K., et al. Study on azithromycin in treatment of diffuse panbronchiolitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 9.12.
  38. Martin D.H., Mroczdowski T.F., Dalu Z.A., et al. A Controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N. Engl. J. Med., 1992, 327: 921-925.
  39. Ridgway G.L. Azithromycin in the management of Chlamydia trachomatis infections. Int. J. STD & AIDS, 1996, 7 (suppl. 1): 5-8.
  40. Lauharanta J., Saarinen K., Mustonen M.-T., et al. Single oral azithromycin versus seven day doxycycline in the treatment of non-gonococcal urethritis in males. J. Antirnicrob. Chemother., 1993, 31 (suppl. E): 177-183.
  41. Lister P.J., Balechandran T., Ridgway G.L., et al. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 185-192.
  42. Centers for Disease Control (CDC) Report. 1993 sexually transmitted diseases treatment guidelines. MMWR, 1993, 42 (RR-14): 47-52.
  43. Simunic V., Vrcic H., Culig J., et al. Single dose of azithromycin in the treatment of sexually transmitted disease in infertile and pregnant women. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.21.
  44. Ballard R.C., Ye H., Matta A., et al. Treatment of chancroid with azithromycin. Int. J. STD & AIDS, 1996, 7 (suppl. 1): 9-12.
  45. Okkerse A., Lijnen R.L.P., Stolz E., et al. The effect of azithromycin given as a single oral dose of 1 gram in men and women with uncomplicated gonorrhoea: a retrospective comparison between capsules and tablets. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 524-527.
  46. Fernandes-Obregon A.C. Azithromycin for the treatment of acne: a retrospective study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996; abstr. 14.08.
  47. Maskell J.P., Sefton A., Williams J.D., et al. A double-blind, placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis ib adults. In: The 3rd International Conference on the Macrolides, Azalides and.Streptogramins. Lisbon, 1996: abstr. 6.05.
  48. Strle F., Cimperman J., Maraspin V., et al. Erythema migrans: clinical and microbiological findings in borrelia culture positive patients treated with azithromycin and doxycycline. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 1.09.
  49. Khan W.A., Seas C., Dhar U., et al. Azithromycin is equivalent to ciprofloxacin in the treatment of shigellosis: results of a randomized, blinded, clinical trial. In: The 36th International Conference on Antimicribial Agents and Chemotherapy. New Orleans, 1996: abstr. LM29.
  50. Butler T., Spidhar C.B., Daga M.K., et al. Treatment of typhoid fever with azithromycin vs chloramphenicol in randomized multicenter trial in India. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. LM-18.
  51. Desnica B., Beus I., Makek N., et al. Azithromycin in the eradication of Helicobacter pylori. Clin. Microbiol. Infect., 1997, 3 (suppl. 2): 232.
  52. Taylor W.R.J., Richie T.L., Fryauff D.J., et al. The tolerance to daily azithromycin malaria prophylaxis by adults in Irian Jaya, Indonesia. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. LM-80.
  53. Girgis N.I., Frenck R.W., Sultan Y. Single dose azithromycin compared to a four dose rifampin regimen for the eradication of meningococcal nasopharyngeal carriage. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. LM-4.
  54. Still J.G. Azithromycin suspension versus penicillin V suspension in the treatment of children with streptococcal pharyngitis. Clin. Parmacol. Ther., 1993, 53: 195.
  55. O’Doherty B. Azithromycin versus penicillin V in the treatment of pediatric patients with acute pharyngitis/tonsillitis. In: The 7th European Congress on Clinical Microbiology and Infectious Diseases. Vienna, 1995: abstr. 1388.
  56. Schaad U.B., Heynen G. The swiss tonsillopharyngitis study group. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. Pediart. Infect. J., 1996, 15: 791-795.
  57. Dagan R., Piglanski L., Yagupski P., et al. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor and amoxycillin. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr, K-103.
  58. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 89-94.
  59. O’Doherty B. Azithromycin versus penicillin V in the treatment of pediatric patients with acute pharyngitis/tonsillitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 3.36.
  60. Mohs E., Rodriguez-Solares A., Rivas E. A comparative study of azithrornycin and amoxicillin in paediatric patients with acute otitis media. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 73-79.
  61. Principi N. Multicentre comparative study of the efficacy and safety of azithrornycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur. J. Clin. Microbiol. Infect. Dis., 1995, 14: 669-676.
  62. Aronovitz G. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr. Infect. Dis. J., 1996, 15: S15-19.
  63. McLynn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr. Infect. Dis. J., 1996, 15: S20-23.
  64. Rodriguez A.F. An open study to compare azithromycin with cefaclor in the treatment of paediatric patients with acute otitis media. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 10.11.
  65. Cassell G.H., Duffy L., Glass J., et al. Evaluation of azithromycin in the treatment of pneumonia associated with Mycoplasma pneumoniae in children. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.14.
  66. Bace A., Kuzmanovic N., Zrnic T. Azithromycin in the treatment of pertussis in children - a pilot study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 8.06.
  67. Principi N., Marchisio P., Biasini G.,et al. Azithromycin versus erythromycin in the treatment of paediatric community-acquired pneumonia. Eur. J. Clin. Res., 1993, 4: 127-133.
  68. Franckart G., Waelbroek A., Demol P., et al. Azithromycin vs. erythromycin in the treatment of lower respiratory tract infections in children. In: The 7th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, 1995: 269.
  69. Harris J., Campbell M., Kolokathis A., et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. In: The 36th Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. LM30.
  70. Ronchetti R., Blasi F., Grossi E., et al. The role of azithromycin in treating children with community-acquired pneumonia. Curr. Ther. Res., 1994, 55: 965-970.
  71. Hofmann D., Schafer V., Springsklee M. Multicentre comparative study of azithromycin versus cefaclor in the treatment of children with acute bacterial lower respiratory tract infections. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.20.
  72. Arguedas A.G., Rodriguez A.F., Zartarian M., et al. An open clinical trial of azithromycin versus amoxicillin/clavulanic acid in the treatment of community-acquired acute lower respiratory tract infections in children. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.19.
  73. Montero L. A comparative study of the efficacy, safety and toleration of azithromycin and cefaclor in the treatment of paediatric patients with acute skin and/or soft tissue infections. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 14.07.
  74. Liu L., Roets E., Busson R., et al. Two novel spiramycins obtained from commercial samples: isolation and elucidation of structure. J. Antibiot., 1996, 49: 398-401.
  75. Arditi M., Yogev R. Spiramycin alone and in combination with trimethoprim against Haemophilus influenzae. J. Antimicrob. Chemother., 1988, 22: 57-62.
  76. Roche Y., Yoshimori R.N. In vitro activity of spiramycin and metronidazole alone or in combination against clinical isolates from odontogenic abscesses. J. Antimicrob. Chemother., 1997, 40: 353-357.
  77. Voss L.M., Farmer K. Cryptosporidium: newly recognized cause of diarrhoea. Curr. Ther., 1987, 9: 23-26.
  78. Smith C.R. The spiramycin paradox. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 141-144.
  79. Bergogne-Berezin E. Predicting antibiotic efficacy in respiratory tract infections. In: The 7th International Congress for Infectious Diseases. Hong Kong, 1996: abstr. 6003.
  80. Watanabe T., Kanno M., Tejima E., et al. Effects of macrolides on ultrastructure of Staphylococcus aureus during the post-antibiotic phase. In: Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy. Berlin, 1991: 726-727.
  81. Desnottes J.F., Diallo N., Santonja R., et al. Effect of subinhibitory concentrations of spiramycin on the adherence of Gram-positive cocci to human cells. Drugs Und. Exper. Clin. Res., 1987, 13: 69-73.
  82. Morikawa K., Oseko F., Morikawa S., et al. Antimicrob. Agents Chemother., 1994, 38: 2643-2647.
  83. Fernandes P.B. The macrolide revival: thirty five years after erythromycin. Antimicrob. Newslet., 1987, 4: 25-44.
  84. Brisson-Noel A., Trieu-Cuot P., Courvalin P. Mechanism of action of spiramycin and other macrolides. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 13-23.
  85. Chabbert Y.A. Early studies on in vitro and experimental activity of spiramycin: a review. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 1-11
  86. Kavi J., Webberly J.M., Andrews J.M., et al. A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 105-110.
  87. Frydman A.M., Le Roux Y., Desnottes J.F., et al. Pharmacokinetics of spiramycin in man. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 93-103.
  88. Lamy P., Antoine D., Zack P., et al. Etude parmacocinetique de la spiramycine en pathologie infectieuse respiratoire. Ann. Med. Nancy, 1977, 16: 109-112.
  89. Bergogne-Berezin E. Spiramycin concentrations in the human respiratory tract: a review. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 117-122.
  90. Bremond G., Magnan J., de Micco C. Sinusites maxillares. Etude clinique, microscopique, ultrastructurale et pharmacologique. J. Fr. Oto-Rhino-Laryngol., 1976, 25, 681-689.
  91. Walstad R.A. Predicting spiramycin efficacy in pneumonia and tonsillitis. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong, 1996: 9-10.
  92. Pocidalo J.J., Albert F., Desnottes J.F., et al. Intraphagocytic penetration of macrolides: in vivo comparison of erythromycin and spiramycin. J. Antimicrob. Chemother., 1985, 16 (suppl. A): 167-173.
  93. Kamme C., Kahlmeter G., Melander A. Evaluation of spiramycin as a therapeutic agent for elimination of nasopharyngeal pathogens. Scand. J. Infect. Dis., 1978, 10: 135-142.
  94. McFarlane J., Mitchell A., Walsh J., et al. Spiramycin in the prevention of postoperative staphylococcal infection. Lancet, 1968, 1: 1-4.
  95. Farhat C.K., Calvalho L.H.F.R., Chung S.S., et al. Toxoplasmosis II. J. Pediatr., 1981, 51: 344-347.
  96. Allen H.H., Khalil M.W., Vachon D., et al. Spiramycin concentrations in female pelvic tissues, determined by HPLC: a preliminary report. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 111-116.
  97. Wise R. Clinical pharmacokinetics of spiramycin. Drug Invest., 1993, 6 (suppl. 1): 29-34.
  98. Dylewski J., Clecner B., Dubois J.,et al. Comparison of spiramycin and doxycycline for treatment of Chlamydia trachomatis genital infections. Antimicrob. Agents Chemother., 1993, 37: 1373-1374.
  99. Decaux ., Devroede C. Acute colitis related to spiramycin. Lancet, 1978, 2: 993.
  100. Perreard M., Klotz F. Oesophagite ulceree apres prise de spiramycine. Ann. Gastroenterol. Hepatol., 1989, 25: 313-314.
  101. Weikel C., Lazenby A., Belitsos P., et al. Intestinal injury associated with spiramycin therapy for Cryptosporidium infection in AIDS. J. Protozool., 1991, 38: 147.
  102. Igea J.M., Quirce S., De la Hoz B., et al. Adverse cutaneous reactions due to macrolides. Ann. Allergy, 1991, 66: 216-218.
  103. Denie C., Henrion J., Schapira M., et al. Spiramycin-induced cholestatic hepatitis. J. Hepatol., 1992, 16: 3.
  104. Osterle L.S., Langtry J.A., Staughton R.C. Allergy to spiramycin during prophylactic treatment of fetal toxoplasmosis. Br. Med. J., 1991, 302: 970.
  105. Soekrawinata t., Ibrahim T., Driyatno E. Spiramycin and erythromycin in the treatment of acute tonsillopharyngitis: a comparative study. Curr. Med. Res. Opin., 1984, 9: 296 300.
  106. Suprihati, Noersinggih, Hoedijono R. Treatment of acute tonsillopharyngitis: a comparative study of spiramycin and erythromycin. Curr. Med. Res. Opin., 1984, 9: 192-196.
  107. Manolopoulos L., Adamopoulos C., Tzagourolakis A., et al. Spiramycin versus penicillin V in the empiric treatment of bacterial tonsillitis. Br. J. Clin. Pract., 1989, 43: 94-96.
  108. Kernbaum S. Tonsillitis. Concours Med., 1988, 110: 2435-2440.
  109. Buyukgebiz B., Buyukgebiz A., Kanra G., et al. Acute maxillary sinusitis treated with spiramycin. Mikrobiyol. Bul., 1987, 21: 181-184.
  110. Boezeman A.J., Kayser A.M., Siemelink R.J.G. Comparison of spiramycin and doxycycline in the empirical treatment of acute sinusitis: preliminary results. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 165-170.
  111. Biermann C., Loken A., Riise R. Comparison of spiramycin and doxycycline in the treatment of lower respiratory tract infections in general practice. J. Anmicrob. Chemother., 1988, 22: 152-158.
  112. De Cock L., Poels R. Comparison of spiramycin with erythromycin for lower respiratory tract infections. J. Antimicrob. Chemother., 1988, 22: 159-163.
  113. Krcmery V., Hrachova J., Nogeova A., et al. Spiramycin versus cefuroximaxetil in initial therapy of pneumonia in children: randomized study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, abstr. 12.01.
  114. Страчунский Л.С., Жаркова Л.П., Авдеева Т.Г. и др. Первое в России контролируемое сравнительное исследование антибиотиков у детей: макропен vs. эритромицин. - Педиатрия, 1995, 4: 123-128.
  115. Страчунский Л.С., Судиловская Н.Н., Ширяева Н.В. и соавт. Спирамицин (ровамицин) - макролидный антибиотик для пероральной терапии внебольничных пневмоний. - Клин. мед., 1995, 2: 45-48.
  116. Mayaud C., Dournon E., Montagne V., et al. Efficacy of IV spiramycin in the treatment of severe legionnaire’s disease, J. Antimicrob. Chemother., 1988, 22 (suppl. В): 179-182.
  117. Vachon F., Kernbaum S. Traitement des bronchopneumopathies aigues par la spiramycine IV. Infectiologie, 1986, 10: 19-23.
  118. Gendrel D., Moulin F., Raymond J., et al. Community acquired pneumonia in children: underestimation of Mycoplasma infection and efficacy of spiramycin and macrolides. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.16.
  119. Sznaider N., Plovano S., Bernat M.I., et al. Effect of spiramycin therapy on human periodontal disease. J. Periodontal Res., 1987, 22: 255-258.
  120. Piccione N. Clinical appraisal of the therapeutic effect of spiramycin-metronidazole association in odontostomatological situations. Minerva Stomatol., 1978, 27: 195-201.
  121. Couly G., Catz G., de Prost Y. Aetiological and therapeutic forms of stomatitis in paediatrics. Rev. Pediatrie, 1986, 22: 363-372.
  122. Delaire J., Talmant J.-C., Le Roux J.-C., et al. Study of an antibacterial combination in stomatological and maxillo-facial surgery. Quest Med., 1973, 26: 1307-1310.
  123. Segev S., Samra Z., Eliav E., et al. The efficacy and safety of spiramycin in the treatment of non-gonococcal urethritis in men. J. Antimicrob. Chemother., 1988, 22 (suppl. В): 183-188.
  124. Wong S.-Y., Remington J.S. Toxoplasmosis in pregnancy. Clin. Infect. Dis., 1994, 18: 853-862.
  125. Gavanou J., Bordes M. Choice of antibiotic therapy following a study of the sensitivity of 568 strains of pathogenic staphylococci. Med. Armee, 1976, 4: 249-253.
  126. Batellier H., Jouk P.S. Value of rovamycin syrup in paediatrics. Lyon Mediterr. Med. Sud-Est, 1982, 17: 5411-5416.
  127. Raymond J., Kalach N., Bergeret M., et al. Influence of antimicrobial resistance on eradication of Helicobacter pylori in infected children. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. LM60.
  128. Aujard Y., Kasse M.C. Prophylaxis of bacterial meningitidis in children. Concours Med., 1986, 108: 559-563.
  129. Engelen F., Vandepitte J. Verbist L., et al. Effect of spiramycin on the nasopharyngeal carriage of Neisseria meningitidis. Chemother., 1981, 27: 325-333.
  130. Ghosh G., Felmingham D., Ridgway G.L. Post-antibiotic effect studies with midecamycin acetate. In: Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy. Berlin, 1991: 2466-2467.
  131. Hamilton-Miller J.M.Т., Shach S. Post-antibiotic effects of miocamycin, roxithromycin and erythromycin on Gram-positive cocci. Int. J. Antimicrob. Agents, 1993, 2: 105-109.
  132. Agostoni C., Giovannini M., Fraschini F., et al. Comparison of miocamycin versus amoxycillin in lower respiratory tract infections in children. Clinical responce and effect on natural killer activity. J. Int. Med. Res., 1988, 16: 305-311.
  133. Tarani L., Teggi A., Bruni L., et al. Studio preliminare sulla farmacocinetica della miocamicina nell’eta pediatrica. Riv. Inf. Ped., 1989, 4: 251-255.
  134. Miglioli P.A., Pivetta P., Orlando R., et al. Pharmacokinetics of miocamycin, in patients with liver cirrhosis. Chemother., 1989, 35: 330-332.
  135. Ivankovic D. Clinical trial on midecamycin: statistical analysis. Midecamycin: data on file. KRKA.
  136. Marchisio P., Calanchi A., Onorato J., et al. Studio multicentrico sulla faringotonsillite in eta pediatrica. Riv. Inf. Ped., 1989, 4: 239-249.
  137. Baba S. Double blind comparison of roxithromycin and midecamycin acetate in the treatment of suppurative otitis media. In: The 16th International Congress of Chemotherapy. Jerusalem, 1989 (abstr.).
  138. Crose G.F., Mazzei L., Zechini F., et al. Terapia con miocamicina della polmonite da Legionella pneumophila: tre casi clinici. Ann. Inst. Forlanini, 1987, 7: 201-212.
  139. Furneri P.M., Roccasalva L., Fallica L., et al. Efficacy of miocamycin in the therapy of non-specific genital infections: non-gonococcal urethritis and acute urethral syndrome. Int. J. Pharm. Res., 1988, 8: 111-116.
  140. Signorelli C., Boni P., Galli M.G. Uso della miocamicina nella terapia delle infezioni cervicali da Chlamydia trachomatis. Clin. Terap., 1988, 124:383-386.
  141. Melloni D., Cacciatore M., Curti Giardina M., et al. Studio clinico comparativo di efficacia e di tollerabilita fra dossiciclina e miocamicina in pazienti con uretroprostatite da Chlamydia trachomatis. Min. Urol. Nefrol., 1987, 39: 355-358.
  142. Karthein J., Spohr M., Traub W.H. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disc diffusion test as compared with erythromycin. Chemother., 1986, 32: 336-343.
  143. Maskell J.P., Sefton A., Cannell H., et al. Predominance of resistant oral streptococci in saliva and the effect of a single course of josamycin or erythromycin. J. Antimicrob. Chemother., 1990, 26: 539-548.
  144. Wildfeuer A., Laufen H., Muller-Wening D., et, al. The effect of antibiotics on the intracellular survival of bacteria in human phagocytic cells. Arzneiin.-Forsch./Drug Res., 1987, 37: 1367-1370.
  145. Cohen L.S., Wechsler A.S., Mitchell J.H., et al. Depression of cardiac function be streptomycin and other antimicrobial agents. Am. J. Cardiol., 1970, 26: 505-511.
  146. Portier H., Houriez-Bernard S., Kazmierczack A., et al. Five days josamycin 1 g b.i.d. vs 10 days Peni V 1 MIU t.i.d. for streptococcal pharingitis/tonsillitis in adults and children over 8 years. In: The 32th Interscience Conference on Antimicribial Agents and Chemotherapy. Anaheim, 1992: abstr. 1678.
  147. Gehanno P., Lescale 0., Scheimberg A., et al. Kinetic of Streptococcus pyogenes eradication in tonsillitis by a 5-day course of josamycin or by a 10-day course of penicillin V. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 3.37.
  148. Baba S., Soyano K., Takasaka T., et al. Evaluation of TE-031 in the treatment of suppurative otitis media: results of a double-blind comparative clinical study with josamycin. Jibi to Rinsho, 1989, 35: 113-133.
  149. Muhlbacher J., Ridi W., Sarffy-Panosch B., et al. Josamycin in comparison with clarithromycin and roxithromycin in the treatment of bronchitis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 447-450.
  150. Periti P. Recenti progressi nella chemioterapia antimicrobica orale: la claritromicina. Farm. Ter., 1990, 7 (suppl. 1): 37-63.
  151. Stahl J.P., Leclerq P., Bru J.P., et al. Empiric therapy of 246 acute pneumonias of adults. In: The 15th International Congress of Chemotherapy. Istanbul, 1987: abstr. 91.
  152. Fedele L. Multicentre epidemiologocal study in ginecology and treatment of Chlamydia trachomatis infections with josamycin. Symposium: Josamycin: New Clinical Perspectives. Paris, 1992.
  153. Soltz-Szotz J., Scheider S., Niebauer B., et al. Significance of the dose of josamycin in the treatment of chlamydia infected pregnant patients. Z. Hautkr., 1989, 64: 129-131.
  154. Hamilton-Miller J.M.T., Maple P.A.C. In vitro assessment of rokitamycin against problem Gram-positive cocci. J. Chemother., 1992, 4: 6-8.
  155. Nagino K., Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin. Microbiol. Infect., 1997, 3: 432-439.
  156. Mukai S., Mukai C., Asaoka K., et al. Use of rokitamycin dry syrup in cases of upper deep cervical lymphadenitis and otitis media with exudatives. J. Japan. Assoc. Infect. Dis., 1989, 63: 98-102.
  157. Finch R.G., Woodhead M.A. Practical conciderations and guidelines for the management of community-acquired pneumonia. Drugs, 1998, 55: 31-45.
  158. Mikasa K., Sawaki M. Kita E., et al. Significant survival benefit of clarithromycin treatment for patients with unrespectable lung cancer. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 4.05.
  159. Sawaki M., Teramoto S., Sakamoto M., et al. Beneficial effects of clarithromycin treatment to inoperable non-small-cell lung cancer patients. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 4.06.
  160. Jenkins C., Blasi F., Allegra L., et al. Chlamydia pneumoniae asthma roxithromycin multinational study (CARM); seroprevalence results. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 4.22.
  161. Fernandes-Obregon A.C. Comparison of azithromycin with other antimicrobials in the treatment of acne. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 4.41.
  162. Ewing P.J., Alder J., Nilius A., et al. Efficacy and potency of anhydrolides, a new class of macrolide antibacterial agents. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 1.28.
  163. Or Y.S., Spina K., Phan L.T., et al. Synthesis and activity of new tricyclic ketolide antibacterial agents. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998: abstr. 1.26.

© 2000-2007 НИИАХ СГМА Rambler's Top100 TopList Rambler's Top100